Advanced Analytical Workflow Solutions for Monitoring Critical Quality Attributes of Monoclonal Antibodies

Recombinant mAbs tend to be unstable and susceptible to modification/degradation. These mAbs need to be identified/monitored for successful drug development. New advanced LC–MS workflows have been developed to meet such needs.